Literature DB >> 25220053

The mTORC1/S6K1 pathway regulates glutamine metabolism through the eIF4B-dependent control of c-Myc translation.

Alfredo Csibi1, Gina Lee1, Sang-Oh Yoon1, Haoxuan Tong2, Didem Ilter3, Ilaria Elia4, Sarah-Maria Fendt4, Thomas M Roberts2, John Blenis5.   

Abstract

Growth-promoting signaling molecules, including the mammalian target of rapamycin complex 1 (mTORC1), drive the metabolic reprogramming of cancer cells required to support their biosynthetic needs for rapid growth and proliferation. Glutamine is catabolyzed to α-ketoglutarate (αKG), a tricarboxylic acid (TCA) cycle intermediate, through two deamination reactions, the first requiring glutaminase (GLS) to generate glutamate and the second occurring via glutamate dehydrogenase (GDH) or transaminases. Activation of the mTORC1 pathway has been shown previously to promote the anaplerotic entry of glutamine to the TCA cycle via GDH. Moreover, mTORC1 activation also stimulates the uptake of glutamine, but the mechanism is unknown. It is generally thought that rates of glutamine utilization are limited by mitochondrial uptake via GLS, suggesting that, in addition to GDH, mTORC1 could regulate GLS. Here we demonstrate that mTORC1 positively regulates GLS and glutamine flux through this enzyme. We show that mTORC1 controls GLS levels through the S6K1-dependent regulation of c-Myc (Myc). Molecularly, S6K1 enhances Myc translation efficiency by modulating the phosphorylation of eukaryotic initiation factor eIF4B, which is critical to unwind its structured 5' untranslated region (5'UTR). Finally, our data show that the pharmacological inhibition of GLS is a promising target in pancreatic cancers expressing low levels of PTEN.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25220053      PMCID: PMC4190129          DOI: 10.1016/j.cub.2014.08.007

Source DB:  PubMed          Journal:  Curr Biol        ISSN: 0960-9822            Impact factor:   10.834


  29 in total

Review 1.  eIF4A: the godfather of the DEAD box helicases.

Authors:  George W Rogers; Anton A Komar; William C Merrick
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2002

2.  HER2 signaling enhances 5'UTR-mediated translation of c-Myc mRNA.

Authors:  Enrico Galmozzi; Patrizia Casalini; Marilena Valeria Iorio; Barbara Casati; Clelia Olgiati; Sylvie Ménard
Journal:  J Cell Physiol       Date:  2004-07       Impact factor: 6.384

3.  Analysis of the c-myc IRES; a potential role for cell-type specific trans-acting factors and the nuclear compartment.

Authors:  M Stoneley; T Subkhankulova; J P Le Quesne; M J Coldwell; C L Jopling; G J Belsham; A E Willis
Journal:  Nucleic Acids Res       Date:  2000-02-01       Impact factor: 16.971

4.  Translational induction of the c-myc oncogene via activation of the FRAP/TOR signalling pathway.

Authors:  M J West; M Stoneley; A E Willis
Journal:  Oncogene       Date:  1998-08-13       Impact factor: 9.867

5.  Characterization of a conserved C-terminal motif (RSPRR) in ribosomal protein S6 kinase 1 required for its mammalian target of rapamycin-dependent regulation.

Authors:  Stefanie S Schalm; Andrew R Tee; John Blenis
Journal:  J Biol Chem       Date:  2005-01-19       Impact factor: 5.157

6.  mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events.

Authors:  Marina K Holz; Bryan A Ballif; Steven P Gygi; John Blenis
Journal:  Cell       Date:  2005-11-18       Impact factor: 41.582

7.  Identification of a conserved motif required for mTOR signaling.

Authors:  Stefanie S Schalm; John Blenis
Journal:  Curr Biol       Date:  2002-04-16       Impact factor: 10.834

8.  AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression.

Authors:  Joseph F Gera; Ingo K Mellinghoff; Yijiang Shi; Matthew B Rettig; Chris Tran; Jung-hsin Hsu; Charles L Sawyers; Alan K Lichtenstein
Journal:  J Biol Chem       Date:  2003-10-23       Impact factor: 5.157

Review 9.  A growing role for mTOR in promoting anabolic metabolism.

Authors:  Jessica J Howell; Stéphane J H Ricoult; Issam Ben-Sahra; Brendan D Manning
Journal:  Biochem Soc Trans       Date:  2013-08       Impact factor: 5.407

10.  The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells.

Authors:  Takayuki Asano; Yixin Yao; Jijiang Zhu; Donghui Li; James L Abbruzzese; Shrikanth A G Reddy
Journal:  Oncogene       Date:  2004-11-11       Impact factor: 9.867

View more
  110 in total

Review 1.  MYC: connecting selective transcriptional control to global RNA production.

Authors:  Theresia R Kress; Arianna Sabò; Bruno Amati
Journal:  Nat Rev Cancer       Date:  2015-09-18       Impact factor: 60.716

Review 2.  mTOR in health and in sickness.

Authors:  Dritan Liko; Michael N Hall
Journal:  J Mol Med (Berl)       Date:  2015-09-22       Impact factor: 4.599

Review 3.  MYC and metabolism on the path to cancer.

Authors:  Annie L Hsieh; Zandra E Walton; Brian J Altman; Zachary E Stine; Chi V Dang
Journal:  Semin Cell Dev Biol       Date:  2015-08-12       Impact factor: 7.727

4.  mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle.

Authors:  Issam Ben-Sahra; Gerta Hoxhaj; Stéphane J H Ricoult; John M Asara; Brendan D Manning
Journal:  Science       Date:  2016-02-12       Impact factor: 47.728

5.  Conformational changes in the activation loop of mitochondrial glutaminase C: A direct fluorescence readout that distinguishes the binding of allosteric inhibitors from activators.

Authors:  Clint A Stalnecker; Jon W Erickson; Richard A Cerione
Journal:  J Biol Chem       Date:  2017-02-14       Impact factor: 5.157

Review 6.  A nexus for cellular homeostasis: the interplay between metabolic and signal transduction pathways.

Authors:  Ana P Gomes; John Blenis
Journal:  Curr Opin Biotechnol       Date:  2015-01-03       Impact factor: 9.740

7.  p62/SQSTM1 Cooperates with Hyperactive mTORC1 to Regulate Glutathione Production, Maintain Mitochondrial Integrity, and Promote Tumorigenesis.

Authors:  Hilaire C Lam; Christian V Baglini; Alicia Llorente Lope; Andrey A Parkhitko; Heng-Jia Liu; Nicola Alesi; Izabela A Malinowska; Darius Ebrahimi-Fakhari; Afshin Saffari; Jane J Yu; Ana Pereira; Damir Khabibullin; Barbara Ogorek; Julie Nijmeh; Taylor Kavanagh; Adam Handen; Stephen Y Chan; John M Asara; William M Oldham; Maria T Diaz-Meco; Jorge Moscat; Mustafa Sahin; Carmen Priolo; Elizabeth P Henske
Journal:  Cancer Res       Date:  2017-05-16       Impact factor: 12.701

Review 8.  MYC, Metabolism, and Cancer.

Authors:  Zachary E Stine; Zandra E Walton; Brian J Altman; Annie L Hsieh; Chi V Dang
Journal:  Cancer Discov       Date:  2015-09-17       Impact factor: 39.397

Review 9.  The molecular rationale for therapeutic targeting of glutamine metabolism in pulmonary hypertension.

Authors:  Thomas Bertero; Dror Perk; Stephen Y Chan
Journal:  Expert Opin Ther Targets       Date:  2019-05-11       Impact factor: 6.902

10.  mTORC1-Driven Tumor Cells Are Highly Sensitive to Therapeutic Targeting by Antagonists of Oxidative Stress.

Authors:  Jing Li; Sejeong Shin; Yang Sun; Sang-Oh Yoon; Chenggang Li; Erik Zhang; Jane Yu; Jianming Zhang; John Blenis
Journal:  Cancer Res       Date:  2016-05-17       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.